ClinicalTrials.gg
CompletedNCT06041256CLARAUpdated Dec 17, 2025Results posted

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

A Phase 1/2 interventional study of AURN001 and Corneal Endothelial Cells in Corneal Edema and Corneal Endothelial Dysfunction, sponsored by Aurion Biotech. Completed at 20 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Aurion Biotech · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Corneal Edema with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Corneal Edema · United States.

Enrollment
6th of 14
97 · median 61
Started
2023
with 3 others
Phase 1/2
Only one
of the 17
Registered
14th of 17
by date
Lead sponsor
2 of 17
Aurion Biotech

Among the 17 studies in Corneal Edema with a site in United States, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 1/2, and was the 14th registered.

Corneal Edema

39 studies on the registry are indexed under Corneal Edema; 8 are open to participants now.

Browse Corneal Edema studies →

Open to participants now

2 of the 17 studies in Corneal Edema with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Corneal Edema studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Corneal Edema with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare different doses of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction. The main questions the clinical trial aims to answer are whether AURN001 effective and safe. Participants will receive a single injection of AURN001. A comparison between low, medium, and high doses of AURN001 against the contribution of each element, cells alone and Y27632 alone, will be conducted to determine the effects on corneal edema.

03

Conditions studied

  • Corneal Edema
  • Corneal Endothelial Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of corneal edema secondary to corneal endothelial dysfunction, requiring surgery (full- or partial-thickness endothelial keratoplasty)
  • BCVA between 65 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters (i.e., 0.4 LogMAR or approximate 20/50 Snellen equivalent) and 5 ETDRS letters (i.e., 1.6 LogMAR or approximate 20/800 Snellen equivalent)

Exclusion criteria

Exclusion Criteria:

  • Have pre-operative corneal epithelial, sub-epithelial or stromal scarring or other opacity that is paracentral/central and visually significant, but not suspected to be secondary to corneal endothelial disease with the potential to improve from treatment in the study eye
  • Have history or presence of an ocular disease other than corneal endothelial dysfunction that could affect vision or safety assessments
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    AURN001 High

    Neltependocel High and Rho-associated protein kinase

    Combination Product: AURN001

  • Experimental
    AURN001 Medium

    Neltependocel Medium and Rho-associated protein kinase

    Combination Product: AURN001

  • Experimental
    AURN001 Low

    Neltependocel Low and Rho-associated protein kinase

    Combination Product: AURN001

  • Experimental
    Neltependocel

    Neltependocel - High

    Biological: Corneal Endothelial Cells

  • Experimental
    ROCK

    Rho-associated protein kinase (ROCK)

    Drug: Y27632

Interventions

  • Combination productAURN001

    Corneal Endothelial Cells and Y27632

  • BiologicalCorneal Endothelial Cells

    Corneal Endothelial Cells

  • DrugY27632

    Y27632

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving ≥15-letter Improvement in Best-corrected Visual Acuity (BCVA) at Month 6 - Imputed Data

    Best-corrected visual acuity was assessed using Early Treatment Diabetic Retinopathy Study(ETDRS) method, standard for vision testing. Standardized Sloan letter charts with 5 letters per line, decreasing by 0.1 logarithm of minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Data presented represent number of participants with available BCVA measurements at Month 6, with those who had missing data, underwent rescue surgery before Month 6, or discontinued study prior to Month 6 imputed as non-responders.

    Time frame: Month 6

Secondary outcomes

  1. Change From Baseline in BCVA at Month 6

    Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.

    Time frame: Baseline (Day 1) and at Month 6

  2. Change From Baseline in Central Corneal Thickness (CCT) at Month 6

    Central corneal thickness was measured by pachymetry which is an essential anatomical marker for detecting the presence or absence of edema and serves as a supportive indicator of treatment efficacy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.

    Time frame: Baseline (Day 1) and at Month 6

  3. Percentage of Participants Achieving ≥15-letter Improvement in BCVA at All Timepoints - Observed Data

    Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. The data presented reflect only participants with non-missing BCVA at each corresponding visit.

    Time frame: At Week 4 and at Months 2, 3, 4.5, 6, 9 and 12

  4. Change From Baseline in BCVA at All Other Timepoints

    Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.

    Time frame: Baseline (Day 1) and at Week 4, Months 2, 3, 4.5, 6, 9 and 12

  5. Change From Baseline in CCT at All Other Timepoints

    Central corneal thickness was measured by pachymetry which is an essential anatomical marker for detecting the presence or absence of edema and serves as a supportive indicator of treatment efficacy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.

    Time frame: Baseline (Day 1) and at Weeks 1 and 4, Months 2, 3, 4.5, 6, 9, and 12

  6. Percentage of Participants Achieving ≥10-letter Improvement in BCVA at All Timepoints - Observed Data

    Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. The data presented reflect only participants with non-missing BCVA at each corresponding visit.

    Time frame: At Week 4 and at Months 2, 3, 4.5, 6, 9 and 12

07

Results

Posted Dec 17, 2025

Participant flow

This was a multicenter, randomized, double-masked, parallel-arm, dose-ranging Phase 1/2 study evaluating safety, efficacy, and tolerability of AURN001 in participants with corneal edema due to endothelial dysfunction. Three dose levels were compared with neltependocel and Y-27632 alone to assess each component's contribution on efficacy and safety of AURN001.

Participant flow — Overall Study
MilestoneY-27632 100 µMNeltependocel 1.0 × 10^6AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Started2118191920
Completed31271217
Not completed1861273
Withdrew: Withdrawal by subject10311
Withdrew: Rescue176962

Outcome measures

PrimaryPercentage of Participants Achieving ≥15-letter Improvement in Best-corrected Visual Acuity (BCVA) at Month 6 - Imputed Data

Best-corrected visual acuity was assessed using Early Treatment Diabetic Retinopathy Study(ETDRS) method, standard for vision testing. Standardized Sloan letter charts with 5 letters per line, decreasing by 0.1 logarithm of minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Data presented represent number of participants with available BCVA measurements at Month 6, with those who had missing data, underwent rescue surgery before Month 6, or discontinued study prior to Month 6 imputed as non-responders.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ≥15-letter Improvement in Best-corrected Visual Acuity (BCVA) at Month 6 - Imputed Data
Percentage of participantsY-27632 100 µMNeltependocel (1.0 × 10^6)AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Percentage of Participants Achieving ≥15-letter Improvement in Best-corrected Visual Acuity (BCVA) at Month 6 - Imputed Data14.344.410.536.850.0
Statistical analysis
  • Y-27632 100 µM vs Neltependocel (1.0 × 10^6) · Fisher Exact · p = 0.0722 · Difference in response rates: 30.2 · 95% CI 0.8 to 58.3
  • Y-27632 100 µM vs AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) · Fisher Exact · p = >0.9999 · Difference in response rates: -3.8 · 95% CI -28.1 to 20.6
  • Y-27632 100 µM vs AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) · Fisher Exact · p = 0.1482 · Difference in response rates: 22.6 · 95% CI -5.5 to 50.6
  • Y-27632 100 µM vs AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) · Fisher Exact · p = 0.0203 · Difference in response rates: 35.7 · 95% CI 5.9 to 61.6
  • Neltependocel (1.0 × 10^6) vs AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) · Fisher Exact · p = 0.0293 · Difference in response rates: -33.9 · 95% CI -60.3 to -4.6
  • Neltependocel (1.0 × 10^6) vs AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) · Fisher Exact · p = 0.7431 · Difference in response rates: -7.6 · 95% CI -38.9 to 25.3
  • Neltependocel (1.0 × 10^6) vs AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) · Fisher Exact · p = 0.7568 · Difference in response rates: 5.6 · 95% CI -26.8 to 37.3
SecondaryChange From Baseline in BCVA at Month 6

Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.

Time frame:
Baseline (Day 1) and at Month 6
Reported as:
Least squares mean · change in ETDRS letters
Change From Baseline in BCVA at Month 6
change in ETDRS lettersY-27632 100 µMNeltependocel (1.0 × 10^6)AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Change From Baseline in BCVA at Month 6-25.5 ± 6.06-5.1 ± 6.41-15.7 ± 6.24-3.0 ± 6.2510.4 ± 6.17
Statistical analysis
  • Y-27632 100 µM vs Neltependocel (1.0 × 10^6) · ANCOVA · p = 0.0232 · Least square mean difference: 20.4 · 95% CI 2.9 to 38.0
  • Y-27632 100 µM vs AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.2600 · Least square mean difference: 9.8 · 95% CI -7.4 to 27.1
  • Y-27632 100 µM vs AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.0115 · Least square mean difference: 22.5 · 95% CI 5.2 to 39.9
  • Y-27632 100 µM vs AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) · ANCOVA · p = <0.0001 · Least square mean difference: 36.0 · 95% CI 18.5 to 53.4
  • Neltependocel (1.0 × 10^6) vs AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.2403 · Least square mean difference: -10.6 · 95% CI -28.4 to 7.2
  • Neltependocel (1.0 × 10^6) vs AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.8138 · Least square mean difference: 2.1 · 95% CI -15.7 to 19.9
  • Neltependocel (1.0 × 10^6) vs AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.0834 · Least square mean difference: 15.5 · 95% CI -2.1 to 33.2
SecondaryChange From Baseline in Central Corneal Thickness (CCT) at Month 6

Central corneal thickness was measured by pachymetry which is an essential anatomical marker for detecting the presence or absence of edema and serves as a supportive indicator of treatment efficacy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.

Time frame:
Baseline (Day 1) and at Month 6
Reported as:
Least squares mean · Microns
Change From Baseline in Central Corneal Thickness (CCT) at Month 6
MicronsY-27632 100 µMNeltependocel (1.0 × 10^6)AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Change From Baseline in Central Corneal Thickness (CCT) at Month 667.5 ± 20.52-7.6 ± 22.17-13.8 ± 21.68-5.6 ± 21.91-14.2 ± 21.82
Statistical analysis
  • Y-27632 100 µM vs Neltependocel (1.0 × 10^6) · ANCOVA · p = 0.0147 · Least square mean difference: -75.1 · 95% CI -135.2 to -15.1
  • Y-27632 100 µM vs AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.0077 · Least square mean difference: -81.3 · 95% CI -140.5 to -22.0
  • Y-27632 100 µM vs AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.0165 · Least square mean difference: -73.1 · 95% CI -132.6 to -13.7
  • Y-27632 100 µM vs AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.0079 · Least square mean difference: -81.7 · 95% CI -141.4 to -22.0
  • Neltependocel (1.0 × 10^6) vs AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.8443 · Least square mean difference: -6.1 · 95% CI -67.8 to 55.6
  • Neltependocel (1.0 × 10^6) vs AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.9490 · Least square mean difference: 2.0 · 95% CI -60.1 to 64.1
  • Neltependocel (1.0 × 10^6) vs AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) · ANCOVA · p = 0.8324 · Least square mean difference: -6.6 · 95% CI -68.1 to 55.0
SecondaryPercentage of Participants Achieving ≥15-letter Improvement in BCVA at All Timepoints - Observed Data

Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. The data presented reflect only participants with non-missing BCVA at each corresponding visit.

Time frame:
At Week 4 and at Months 2, 3, 4.5, 6, 9 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥15-letter Improvement in BCVA at All Timepoints - Observed Data
percentage of participantsY-27632 100 µMNeltependocel (1.0 × 10^6)AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Week 44.85.910.55.310.0
Month 2016.70010.0
Month 36.735.311.821.126.3
Month 4.5042.914.329.436.8
Month 650.057.116.743.852.6
Month 933.358.337.538.550.0
Month 12058.328.666.776.5
SecondaryChange From Baseline in BCVA at All Other Timepoints

Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.

Time frame:
Baseline (Day 1) and at Week 4, Months 2, 3, 4.5, 6, 9 and 12
Reported as:
Mean · change in ETDRS letters
Change From Baseline in BCVA at All Other Timepoints
change in ETDRS lettersY-27632 100 µMNeltependocel (1.0 × 10^6)AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Week 4-28.7 ± 24.57-24.6 ± 33.16-27.8 ± 29.64-26.9 ± 25.04-16.9 ± 27.14
Month 2-17.2 ± 21.69-20.5 ± 37.31-26.6 ± 29.37-24.3 ± 27.63-12.1 ± 28.37
Month 3-19.6 ± 25.82-8.1 ± 40.76-10.6 ± 22.64-9.2 ± 27.960.2 ± 21.73
Month 4.5-21.2 ± 26.51-8.9 ± 39.80-11.6 ± 26.97-4.1 ± 28.075.4 ± 19.90
Month 6-21.2 ± 28.63-5.6 ± 40.48-15.2 ± 25.26-3.9 ± 28.306.8 ± 18.67
Month 9-21.4 ± 28.15-5.5 ± 41.19-13.1 ± 26.36-3.8 ± 28.548.2 ± 18.98
Month 12-21.5 ± 28.00-1.2 ± 40.29-14.3 ± 26.16-1.6 ± 30.308.8 ± 21.46
SecondaryChange From Baseline in CCT at All Other Timepoints

Central corneal thickness was measured by pachymetry which is an essential anatomical marker for detecting the presence or absence of edema and serves as a supportive indicator of treatment efficacy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.

Time frame:
Baseline (Day 1) and at Weeks 1 and 4, Months 2, 3, 4.5, 6, 9, and 12
Reported as:
Mean · Microns
Change From Baseline in CCT at All Other Timepoints
MicronsY-27632 100 µMNeltependocel (1.0 × 10^6)AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Week 187.4 ± 89.76116.9 ± 134.5993.4 ± 155.8169.4 ± 86.47117.0 ± 138.71
Week 497.5 ± 117.8177.3 ± 102.4035.1 ± 126.5840.7 ± 57.7466.0 ± 78.97
Month 263.7 ± 61.4064.4 ± 100.3847.9 ± 45.152.6 ± 45.8836.9 ± 72.53
Month 360.8 ± 115.35-4.6 ± 114.97-16.1 ± 94.48-1.6 ± 76.7220.8 ± 68.96
Month 4.566.9 ± 117.556.3 ± 113.65-25.0 ± 110.49-11.8 ± 76.226.8 ± 65.26
Month 665.7 ± 116.75-5.7 ± 112.03-20.2 ± 110.13-16.7 ± 66.352.6 ± 70.27
Month 964.8 ± 122.48-15.5 ± 112.88-21.0 ± 114.96-37.3 ± 74.17-21.7 ± 50.56
Month 1263.0 ± 114.77-22.4 ± 107.81-19.1 ± 113.35-31.8 ± 68.25-7.6 ± 89.14
SecondaryPercentage of Participants Achieving ≥10-letter Improvement in BCVA at All Timepoints - Observed Data

Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. The data presented reflect only participants with non-missing BCVA at each corresponding visit.

Time frame:
At Week 4 and at Months 2, 3, 4.5, 6, 9 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥10-letter Improvement in BCVA at All Timepoints - Observed Data
percentage of participantsY-27632 100 µMNeltependocel (1.0 × 10^6)AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Week 44.811.815.85.310.0
Month 2016.714.312.540.0
Month 36.747.111.831.631.6
Month 4.516.750.021.435.352.6
Month 650.057.116.743.857.9
Month 933.383.337.553.877.8
Month 1233.383.342.966.782.4

Adverse events

Collected over From first dose (Day 1) through Month 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Y-27632 100 µM0/21 (0%)1/21 (4.8%)9/21 (42.9%)
Neltependocel 1.0 × 10^60/18 (0%)1/18 (5.6%)11/18 (61.1%)
AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)0/19 (0%)0/19 (0%)10/19 (52.6%)
AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)0/19 (0%)0/19 (0%)18/19 (94.7%)
AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)0/20 (0%)0/20 (0%)14/20 (70%)
Most frequent serious events
Most frequent serious events
EventY-27632 100 µMNeltependocel 1.0 × 10^6AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Femur fractureInjury, poisoning and procedural complications0/211/180/190/190/20
Hip fractureInjury, poisoning and procedural complications1/210/180/190/190/20
Most frequent other events
Showing 10 of 50
Most frequent other events
EventY-27632 100 µMNeltependocel 1.0 × 10^6AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)
Ocular hypertensionEye disorders3/212/183/192/191/20
ConjunctivitisInfections and infestations0/210/180/193/190/20
SinusitisInfections and infestations0/210/181/193/190/20
Corneal abrasionInjury, poisoning and procedural complications0/212/180/192/190/20
InfluenzaInfections and infestations0/212/180/190/190/20
Dry eyeEye disorders0/210/182/190/192/20
COVID-19Infections and infestations0/210/181/192/190/20
Epiretinal membraneEye disorders0/210/180/192/190/20
Conjunctival haemorrhageEye disorders2/210/181/191/192/20
Endocrine ophthalmopathyEye disorders0/210/180/190/192/20

Baseline characteristics

Full Analysis Set comprised of all randomized participants who received any amount of study drug during intracameral injection.

Age, Continuous
Age, Continuous(Years)Y-27632 100 µMNeltependocel 1.0 × 10^6AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)Total
Mean70.3 ± 9.5971.3 ± 9.9374.7 ± 10.3269.3 ± 6.9171.6 ± 8.2871.4 ± 9.08
Sex: Female, Male
Sex: Female, Male(Participants)Y-27632 100 µMNeltependocel 1.0 × 10^6AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)Total
Female11141051555
Male104914542
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Y-27632 100 µMNeltependocel 1.0 × 10^6AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)Total
Hispanic or Latino011002
Not Hispanic or Latino211718172093
Unknown or Not Reported000202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Y-27632 100 µMNeltependocel 1.0 × 10^6AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM)AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM)Total
American Indian or Alaska Native000000
Asian101002
Native Hawaiian or Other Pacific Islander000000
Black or African American201115
White181715181987
More than one race010001
Unknown or Not Reported002002
08

Study locations

20 sites
  • Aurion Biotech site
    Little Rock, Arkansas 72205, United States
  • Aurion Biotech site
    Los Angeles, California 90067, United States
  • Aurion Biotech site
    San Francisco, California 94158, United States
  • Aurion Biotech site
    Atlanta, Georgia 30339, United States
  • Aurion Biotech site
    Indianapolis, Indiana 46260, United States
  • Aurion Biotech site
    Wichita, Kansas 67206, United States
  • Aurion Biotech site
    Minnetonka, Minnesota 55305, United States
  • Aurion Biotech site
    Garden City, New York 11576, United States
  • Aurion Biotech site
    Winston-Salem, North Carolina 27157, United States
  • Aurion Biotech site
    Cincinnati, Ohio 45242, United States
  • Aurion Biotech site
    Oklahoma City, Oklahoma 73104, United States
  • Aurion Biotech site
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Aurion Biotech site
    Sioux Falls, South Dakota 57108, United States
  • Aurion Biotech site
    Houston, Texas 77027, United States
  • Aurion Biotech site
    Houston, Texas 77055, United States
  • Aurion Biotech site
    Norfolk, Virginia 23502, United States
  • Aurion Biotech site
    Seattle, Washington 98125, United States
  • Aurion Biotech site
    Vancouver, British Columbia V5Z 1K1 CAN, Canada
  • Aurion Biotech site
    Oakville, Ontario L6H 0J8 CAN, Canada
  • Aurion Biotech site
    Toronto, Ontario M5T 3A9 CAN, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Oct 2024, 12 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 18, 2023
StartActual
Oct 18, 2023
Primary completionActual
Oct 25, 2024
CompletionActual
Apr 15, 2025
Results first posted
Dec 17, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06041256
Lead sponsor
Aurion Biotech
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Oct 18, 2023
Primary completion
Oct 25, 2024
Completion
Apr 15, 2025
Results posted
Dec 17, 2025
Last update
Dec 17, 2025

Study contacts

Study Manager, OD
study director · Aurion Biotech

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion